Amryt Pharma plc (AMYT) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED 2025
What happened to Amryt Pharma plc (AMYT) stock?
Amryt Pharma plc (AMYT) no longer trades on public markets. It was delisted in January 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Amryt Pharma plc (AMYT). Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.
Last analyzed: Sep 7, 2026Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East.
Analyst Coverage for AMYT: AMYT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMYT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
AMYT: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Amryt Pharma plc Company Overview
Who Are AMYT's Competitors?
AMYT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MKKGY Merck KGaA | $30.49 | -1.20% | $66.3B | 499-signal |
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $36.10 | -2.04% | $42.0B | 605-pillar |
| HLN Haleon plc | $9.22 | -0.11% | $40.6B | 775-pillar |
| SDZNY Sandoz Group AG | $81.08 | -2.68% | $35.1B | 519-signal |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
| SGIOY Shionogi & Co., Ltd. | $9.04 | +0.22% | $15.4B | 619-signal |
| ELAN Elanco Animal Health Incorporated | $22.86 | -2.93% | $11.4B | 335-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are the Key Risks for AMYT?
Negative return on equity (-9.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 16 days old
- ● No filing on record
- ● No analyst coverage
Financial Health
Amryt Pharma plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Amryt Pharma plc stands at -9.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.3%, showing how much profit it generates from its asset base. A current ratio of 1.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.6%, the inverse of the P/E and a quick read on earnings relative to price.
Earnings Track Record
Amryt Pharma plc has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 60.5% above estimates on average.
AMYT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
AMYT Latest News
-
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
benzinga · Jan 9, 2023
-
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jan 9, 2023
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Jan 9, 2023
-
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
benzinga · Jan 9, 2023
Latest News
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Health Care Stocks Moving In Monday's Intraday Session
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
Amryt Pharma plc ADR Information Sponsored
Amryt Pharma plc (AMYT) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About Amryt Pharma plc (AMYT)
What happened to Amryt Pharma plc (AMYT) stock?
Amryt Pharma plc (AMYT) no longer trades on public markets. It was delisted in January 2025. The figures below are historical and are not a current quote.
Can I still buy AMYT shares?
No. AMYT stopped trading on public markets in January 2025, so the shares are not available through a broker. Anything you see quoted for AMYT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AMYT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Amryt Pharma plc. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.